Skip to main content

Day: May 2, 2024

Intapp acquires Transform Data International

Acquisition enhances Microsoft 365 work capabilities and implementation services for Intapp Collaboration solutions PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) — Intapp (NASDAQ: INTA), a leading global provider of AI-powered software for professionals at advisory, legal, and capital markets firms, today announced that it has acquired Transform Data International (TDI). TDI is exclusively focused on delivering easy-to-use digital workplaces, based on Microsoft 365 applications, for professional services firms. Transform Data International is a longtime Intapp partner that builds and implements enterprise collaboration technology. The company has developed its own portfolio of software add-ons for Intapp Collaboration solutions, which it delivers to clients in more than 15 countries. TDI’s Workhub solution provides a familiar,...

Continue reading

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm

LAS VEGAS, May 02, 2024 (GLOBE NEWSWIRE) — Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence (AI) technology company specializing in the development of advanced AI and data center infrastructure solutions, has named William Hisey as the Company’s new Chief Executive Officer (CEO), effective immediately. Hisey comes to Avant via its acquisition of Wired4Health, a healthcare technology and data integration firm, where he’s spent the last 13 years serving as the firm’s Chief Financial Officer (CFO). Hisey joins Avant at a pivotal moment in the Company’s growth. Avant spent the past year laying the groundwork for its future in the AI industry, and William Hisey will bring his 25 years of experience in business operations and finance, including executive-level positions in private equity and...

Continue reading

Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended March 31, 2024 and Declaration of Distributions on Common Stock for the Months Ending July 31, August 31, and September 30, 2024

GREENWICH, Conn., May 02, 2024 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended March 31, 2024. On April 25, 2024, our Board of Directors declared the following distributions on our common stock: Month Ending Record Date Payment Date Amount Per Share July 31, 2024 July 17, 2024 July 31, 2024 $0.035 August 31, 2024 August 16, 2024 August 30, 2024 $0.035 September 30, 2024 September 16, 2024 September 30, 2024 $0.035         Net asset value (“NAV”) per share as of March 31, 2024 stood at $2.42, compared with a NAV per share on December 31, 2023 of $2.55. Net investment income (“NII”) was approximately $6.5 million, or $0.11 per share, for the quarter...

Continue reading

GigaCloud Technology Inc to Announce First Quarter 2024 Financial Results and Host Conference Call on May 9, 2024

EL MONTE, Calif., May 02, 2024 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024 before the market opens on Thursday, May 9, 2024. The Company will host a conference call to discuss its financial results on the same day at 8:00 AM Eastern Time. To access the conference call, participants should pre-register here to receive the dial-in information and a unique PIN. All participants are encouraged to dial-in 15 minutes prior to the conference call’s start time. A live and archived webcast of the conference call will be accessible on the Company’s investor relations website at https://investors.gigacloudtech.com/news-events/events. About...

Continue reading

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered into a definitive agreement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) in a private placement at a purchase price per share of $6.5015, priced at-the-market under Nasdaq rules. The Company expects to receive gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering. The company intends to use the net...

Continue reading

Landsbankinn hf.: Financial results of Landsbankinn for the first three months of 2024

Landsbankinn’s net profit in the first three months of 2024 was ISK 7.2 billion. Return on equity (ROE) in the period was 9.3%, compared with 11.1% for the same period the previous year. The net interest margin was 2.9%. The net interest margin of domestic households was 2% and remains stable. Net interest income amounted to ISK 14.4 billion and net fee and commission income was ISK 2.7 billion. Net impairments were negative by ISK 2.7 billion and include an ISK 2.0 billion collective allowance against uncertainty related to natural disaster on the Reykjanes peninsula. The cost/income ratio was 33.6%, compared with 33.3% in the first quarter of 2023. The total capital ratio was 24.9% at the end of the period. The total capital requirement of the Financial Supervisory Authority of the Central Bank of Iceland is 20.7%. In March, Landsbankinn...

Continue reading

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided comments on the protocol of a planned clinical trial that will study the use of tafenoquine in treating babesiosis. Babesiosis, a potentially life-threatening disease in immunosuppressed patients, is a tick-borne illness steadily emerging in the United States. The FDA had some questions and recommendations that will be addressed. Nothing in the comments requires the Company to change the trial design/protocol in a material way. The Company is continuing preparatory actions to facilitate initiation of...

Continue reading

Subsea7: Subsea Integration Alliance collaboration agreement with Equinor; Commencing work on Wisting and Bay du Nord

Luxembourg – 2 May 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the signing of a new long-term strategic collaboration agreement between Equinor and Subsea Integration Alliance (which comprises Subsea7 and OneSubsea). The agreement, which was signed today in Stavanger, Norway, represents an innovative, integrated way of working. It enables early information sharing and other collaborative benefits critical to unlocking subsea projects by making them economically viable. Building on their experience as members of Subsea Integration Alliance, this agreement also further cements Subsea7 and OneSubsea’s positions as trusted contractors to Equinor. The agreement paves the way for exclusive collaboration to begin immediately on early, joint concept studies for two projects: the Wisting field offshore Norway, and Bay...

Continue reading

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

May 2, 2024News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, May 2, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter ending March 31, 2024, the Company’s management team will host an online investor presentation on May 8th, 2024 at 11:00 CEST via HC Andersen Capital. Investors interested in attending the webcast may register here: https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2024.  Additionally, the Company’s management team will host a physical investor meeting on May 8th, 2024, at 15:00 CEST at the Company’s address...

Continue reading

CoreCard Corporation Reports First Quarter 2024 Results

NORCROSS, Ga., May 02, 2024 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2024. “Overall revenue of $13.1 million in the first quarter was in-line with our expectations, reflecting continued year-over-year growth in processing and maintenance of 13%, which was offset by lower professional services revenue, primarily driven by our largest customer,” said Leland Strange, CEO of CoreCard. “We continue to see encouraging results from the ongoing investment in our platform and processing capabilities, and we continue to onboard new customers that value the features and functionality...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.